Chenhong Zheng1, Shouying Liu2, Peiliang Geng3, Huiming Zhang4, Hongpeng Zhang5, Airong Tang5, Xiaohua Xie5. 1. First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China ; No. 2 Clinic, Management Support Bureau, Chinese PLA General Logistics Department Beijing 100071, China. 2. Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support Bureau Beijing 100071, China. 3. Cancer Center, Chinese PLA General Hospital & Chinese PLA Medical School No. 28 Fuxing Road, Haidian District, Beijing 100853, China. 4. No. 2 Clinic, Management Support Bureau, Chinese PLA General Logistics Department Beijing 100071, China. 5. First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China.
Abstract
OBJECTIVES: To assess the efficacy and safety of edaravone for myocardial damage during myocardial ischemia and reperfusion (I/R). METHODS: We included randomized controlled trials that compared edaravone with placebo or no intervention in patients with acute myocardial infarction or undergoing coronary artery bypass. Two authors selected eligible trials, assessed trial quality and independently extracted the data. RESULTS: Seven clinical trials were eventually included and analyzed in this study, involving 148 participants. Four trials were defined as waiting assessment. All of the three remaining trials compared edaravone and another treatment combined with other treatment alone, used the same dose of edaravone injections (60 mg per day) and course of treatment (14 days), evaluated the effect of edaravone at different times, applied different methods, reported adverse events, and showed no differences between the treatment group and the control group. When pooling all of the trials in one dataset, edaravone appeared to decrease the proportion of participant with marked myocardial damage during I/R as compared with the control group. The meta-analysis also revealed decreased CK-MB, cTnI and MDA, and increased content of SOD. CONCLUSIONS: Due to the moderate risk of bias and small sample, our observation of an effective treatment trend of edaravone for I/R requires future larger, high-quality trials to confirm.
OBJECTIVES: To assess the efficacy and safety of edaravone for myocardial damage during myocardial ischemia and reperfusion (I/R). METHODS: We included randomized controlled trials that compared edaravone with placebo or no intervention in patients with acute myocardial infarction or undergoing coronary artery bypass. Two authors selected eligible trials, assessed trial quality and independently extracted the data. RESULTS: Seven clinical trials were eventually included and analyzed in this study, involving 148 participants. Four trials were defined as waiting assessment. All of the three remaining trials compared edaravone and another treatment combined with other treatment alone, used the same dose of edaravone injections (60 mg per day) and course of treatment (14 days), evaluated the effect of edaravone at different times, applied different methods, reported adverse events, and showed no differences between the treatment group and the control group. When pooling all of the trials in one dataset, edaravone appeared to decrease the proportion of participant with marked myocardial damage during I/R as compared with the control group. The meta-analysis also revealed decreased CK-MB, cTnI and MDA, and increased content of SOD. CONCLUSIONS: Due to the moderate risk of bias and small sample, our observation of an effective treatment trend of edaravone for I/R requires future larger, high-quality trials to confirm.
Authors: D Altavilla; B Deodato; G M Campo; M Arlotta; M Miano; G Squadrito; A Saitta; D Cucinotta; S Ceccarelli; M Ferlito; M Tringali; L Minutoli; A P Caputi; F Squadrito Journal: Cardiovasc Res Date: 2000-08-18 Impact factor: 10.787